Ameritas Investment Partners
HUMA icon

Ameritas Investment Partners’s Humacyte HUMA Stock Holding History

Ameritas Investment Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,796
Closed -$7.76K – 3250
2026
Q1 		$7.76K Hold
12,796
– – ﹤0.01% 2912
2025
Q4 		$12.3K Hold
12,796
– – ﹤0.01% 2847
2025
Q3 		$22.3K Hold
12,796
– – ﹤0.01% 2609
2025
Q2 		$26.7K Buy
12,796
+4,184
+49% +$8.04K ﹤0.01% 2529
2025
Q1 		$14.7K Hold
8,612
– – ﹤0.01% 2678
2024
Q4 		$43.5K Hold
8,612
– – ﹤0.01% 2269
2024
Q3 		$46.8K Hold
8,612
– – ﹤0.01% 2229
2024
Q2 		$41.3K Buy
8,612
+3,908
+83% +$20.3K ﹤0.01% 2243
2024
Q1 		$14.6K Hold
4,704
– – ﹤0.01% 2685
2023
Q4 		$13.4K Hold
4,704
– – ﹤0.01% 2748
2023
Q3 		$13.8K Hold
4,704
– – ﹤0.01% 2698
2023
Q2 		$13.5K Hold
4,704
– – ﹤0.01% 2778
2023
Q1 		$14.5K Hold
4,704
– – ﹤0.01% 2576
2022
Q4 		$12.4K Buy
4,704
+3,381
+256% +$10.3K ﹤0.01% 2748
2022
Q3 		$4K Hold
1,323
– – ﹤0.01% 2946
2022
Q2 		$4K Buy
+1,323
New +$7.36K ﹤0.01% 2977

Other funds holding HUMA

Antipodes Partners
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Davidson Kempner Capital Management
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ameritas Investment Partners's HUMA Position: Q2 2026 in Review

Ameritas Investment Partners sold out of Humacyte (HUMA) in Q2 2026, closing a stake of 12,796 shares — an estimated $7.76K sold.

Ameritas Investment Partners first reported a position in HUMA in Q2 2022 and held it in 16 quarters. The position peaked at $46.8K in Q3 2024. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Ameritas Investment Partners reported no remaining Humacyte position as of Q2 2026 after selling out during the quarter.
  • Ameritas Investment Partners sold 12,796 Humacyte shares in Q2 2026, an estimated $7.76K.
  • Ameritas Investment Partners first reported a position in Humacyte in Q2 2022 and held it in 16 quarters.
  • Ameritas Investment Partners's Humacyte position peaked at $46.8K in Q3 2024.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.